Track topics on Twitter Track topics that are important to you
Firstview Insight's Oral Mucositis Pricing Market Access and Landscape 2019 provides country specific insights in order to estimate market potential for Oral Mucositis based on the pricing and reimbursement scenario and perceived value drivers in different market archetypes. It gives a detailed picture of the disease landscape and unmet needs of different stakeholders existing in the current treatment paradigmThus it enables to identify and leverage on the commercial opportunities spanning across different lines of therapy. The report incorporates detailed analysis of the market development drivers as well as the preventing factors. The scope of the report covers an extensive estimation pertaining to the winning essentials and participant schemes through a presentation of the segmentation of market in the Pricing Market Access landscape.
Oral mucositis is a common complication of cancer chemotherapy. It begins 510 days after the initiation of chemotherapy and lasts 714 days. Chemotherapyinduced oral mucositis causes the mucosal lining of the mouth to atrophy and break down, forming ulcers.Mucositis occurs when cancer treatments break down the rapidly divided epithelial cells lining the gastrointestinal tract which goes from the mouth to the anus, leaving the mucosal tissue open to ulceration and infection. Mucosal tissue, also known as mucosa or the mucous membrane, lines all body passages that communicate with the air, such as the respiratory and alimentary tracts, and have cells and associated glands that secrete mucus. The part of this lining that covers the mouth, called the oral mucosa, is one of the most sensitive parts of the body and is particularly vulnerable to chemotherapy and radiation. The oral cavity is the most common location for mucositis.
Oral mucositis is probably the most common, debilitating complication of cancer treatments, particularly chemotherapy and radiation. It can lead to several problems, including pain, nutritional problems as a result of inability to eat, and increased risk of infection due to open sores in the mucosa. It has a significant effect on the patient's quality of life and can be doselimiting i.e., requiring a reduction in subsequent chemotherapy doses.
Signs of Mucositis
Signs and symptoms of mucositis include:
Red, shiny, or swollen mouth and gums
Blood in the mouth
Sores in the mouth or on the gums or tongue
Soreness or pain in the mouth or throat
Difficulty swallowing or talking
Feeling of dryness, mild burning, or pain when eating food
Soft, whitish patches or pus in the mouth or on the tongue
Increased mucus or thicker saliva in the mouth
An extreme case of the condition is called confluent mucositis. In a worst case, the mucous membrane of the patient's entire mouth and tongue can be coated by a white mucus coating that is up to a millimeter thick. The combination of mucus, excess saliva and pain can make it difficult or even impossible to treat.
Scope of the Report:
Market Access strategy for different payer archetypes
Segmentation and mapping of payers to different archetypes based on their specific criteria of assessment i.e. costeffectiveness, budget impact, clinical effectiveness. This would enable designing effective market strategy for reimbursement in these markets. It also covers the reimbursement decisions and benefit ratings of competitor drugs by different health technology assessment bodies in EU5,US and Japan.
Payer Policy changes and implications
Provides an overview of the changing payer preferences, concerns and evolving requirements. Informs about the payer policies impacting the prescription and uptake of particular product. Estimates the future payer environment and drivers of change.
Innovative pricing and funding mechanisms
With increasing pressure from payers and limitations in evidence development, many innovative payment mechanisms are being introduced such as outcome based reimbursement, annuity based funding etc. This section provides examples of such innovative models and feasibility of their application in a particular disease scenario.
This report contains comprehensive overview of disease including disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends, as well as details about treatment algorithms and treatment guidelines
This section encompasses information on the incidence and prevalence of disease in EU5, US Japan.
Existing and upcoming treatment landscape
Captures the evolution of treatment paradigm including the current and emerging drug therapies. Provides information on the clinical trial results, mechanism of action, route of administration, therapeutic positioning and regulatory milestones. It gives insight into the potential therapeutic targets for drug development.
Market Trends Unmet needs
This section of the report helps to understand the market trend and opportunities by analysing the impact of current therapies on the market, current and future unmet needs, drivers and barriers and demand of better technology. This is determined by analysing the impact of various factors such as mechanism of action, route, cost of therapy, patient segmentation, existing available treatments, compliance and need of the market, expected launch timelines, competitors, brand value and KOLs perception.
Major highlights of the report
Detailed analysis of existing and upcoming competitive landscape
HTA decisions and benefit ratings for :
HASASMR and SMRFrance
Market archetyping and product positioning
Case studies on innovative funding models
Unmet need, major barriers and drivers across the industry:
Value story for achieving reimbursement and premium pricing in different marketsNEXT ARTICLE
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...